Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Phase II Reactions: Methylation Reactions01:17

Phase II Reactions: Methylation Reactions

917
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
917
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

392
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
392
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

732
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
732
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

72
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

82
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
82
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

132
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
132

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prescription opioid analgesic use in France: Trends and impact on morbidity-mortality.

European journal of pain (London, England)·2018
Same author

Safety of intravitreal injection of ranibizumab in early pregnancy: a series of three cases.

Eye (London, England)·2018
Same author

[Evidence-based evaluation and expertise of methotrexate off label use in gynaecology and obstetrics: work of the CNGOF].

Journal de gynecologie, obstetrique et biologie de la reproduction·2015
Same author

The PREGVAXGRIP study: a cohort study to assess foetal and neonatal consequences of in utero exposure to vaccination against A(H1N1)v2009 influenza.

Drug safety·2013
Same author

[Acetaminophene-induced hypotension in intensive care unit: a prospective study].

Annales francaises d'anesthesie et de reanimation·2009
Same author

[Thromboembolic events at the time of highly active antiretroviral therapies against human immunodeficiency virus].

La Revue de medecine interne·2008
Same journal

[Neuroprotection for preterm infants with antenatal magnesium sulphate].

Journal de gynecologie, obstetrique et biologie de la reproduction·2017
Same journal

[Is universal screening for cervical length among singleton pregnancies with no history of preterm birth justified?]

Journal de gynecologie, obstetrique et biologie de la reproduction·2017
Same journal

[Lifestyle recommendations for prevention of spontaneous preterm birth in asymptomatic pregnant women].

Journal de gynecologie, obstetrique et biologie de la reproduction·2017
Same journal

[Guidelines for clinical practice: Prevention of spontaneous preterm birth (excluding preterm premature rupture of membranes) - Introduction].

Journal de gynecologie, obstetrique et biologie de la reproduction·2017
Same journal

[Psychological aspects of abortion].

Journal de gynecologie, obstetrique et biologie de la reproduction·2016
Same journal

[Induced abortion: Guidelines for clinical practice - Introduction].

Journal de gynecologie, obstetrique et biologie de la reproduction·2016
See all related articles

Related Experiment Video

Updated: Apr 17, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K

[Methotrexate pharmacology].

L Lagarce1, M Zenut2, P Lainé-Cessac1

  • 1Centre régional de pharmacovigilance, CHU d'Angers, 4, rue Larrey, 49933 Angers cedex 9, France.

Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction
|February 10, 2015
PubMed
Summary
This summary is machine-generated.

Methotrexate, a folic acid analog, inhibits key enzymes and is used in various medical fields. This review focuses on its pharmacology, particularly for treating ectopic pregnancies.

Keywords:
Ectopic pregnancyGrossesse extra-utérineMethotrexateMéthotrexatePharmacologiePharmacology

More Related Videos

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

3.3K
Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
09:04

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Published on: September 10, 2018

10.2K

Related Experiment Videos

Last Updated: Apr 17, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K
Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

3.3K
Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
09:04

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Published on: September 10, 2018

10.2K

Area of Science:

  • Pharmacology
  • Biochemistry
  • Drug Action

Context:

  • Methotrexate is a folic acid analog with diverse clinical applications.
  • Its mechanism involves inhibiting thymidylate synthetase and dihydrofolate reductase.
  • Off-label use in ectopic pregnancy treatment is a significant area of interest.

Purpose:

  • To review the pharmacology of methotrexate.
  • To focus on data relevant to its use in ectopic pregnancies.
  • To provide a comprehensive overview for clinicians and researchers.

Summary:

  • Methotrexate, a dihydrofolate reductase inhibitor, is explored for its pharmacological profile.
  • The review details its action as a folic acid antagonist.
  • Emphasis is placed on its efficacy and safety in managing ectopic pregnancies.

Impact:

  • Enhances understanding of methotrexate's mechanism of action.
  • Provides critical data for optimizing ectopic pregnancy treatment protocols.
  • Supports evidence-based practice in reproductive medicine and oncology.